Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR.

G Horigan, H McNulty, M Ward, JJ STRAIN, J Purvis, J.M. Scott

Research output: Contribution to journalArticle

53 Citations (Scopus)


Objective: The purpose was to examine the effect of intervention with riboflavin (a cofactor for MTHFR) on blood pressure in patients homozygous (TT genotype) for the common 677C->T polymorphism in MTHFR.Methods: We investigated 197 premature cardiovascular disease patients, prescreened for the MTHFR 677C->T polymorphism, from an original cohort of 404 to select those with the TT genotype (n = 60) and a similar number with heterozygous (CT; n = 85) or wild-type (CC; n = 75) genotypes. Of these, 181 completed an intervention in which participants were randomized within each genotype group to receive 1.6 mg per day riboflavin or placebo for 16 weeks.Results: Among patients taking one or more antihypertensive drugs at recruitment (82%), we observed that target blood pressure (
Original languageEnglish
Pages (from-to)478-486
JournalJournal of Hypertension
Publication statusPublished - Mar 2010


Cite this